Hong Kong stocks CRO concept sector changes, many stocks closed up more than 7
Time of Update: 2022-08-15
As of the close, Zhaoyan New Drug rose by the daily limit, with an increase of 10%, WuXi Biologics rose by more than 8%, GenScript Biotechnology, Kay Laying rose more than 7%, Tiger Pharmaceuticals, WuXi PharmaTech and others followed suit [Pharmaceutical Network Pharmaceutical Stock Market] On July 4, the CRO concept sector of Hong Kong stocks changed, and many stocks rose significantly.
For the treatment of gastroesophageal reflux disease, 4 new blockbuster drugs should not be missed
Time of Update: 2021-04-19
In addition, data from phase III clinical trials show that the safety of voroxane for the treatment of reflux esophagitis and other gastric acid-related diseases is similar to that of PPI drugs .
Inventory: 15 T790M "EGFR-TKI" under study in China
Time of Update: 2021-03-05
July 2017, Jiangsu Meido Pharmaceutical Research and Development Co., Ltd. submitted a clinical trial application (Class 1) to CDE and obtained clinical implied permission in December 2017; 03ES-072 (Bosheng Pharmaceuticals) Development Company for Bosheng Pharmaceuticals, EGFR (L858R, ex19del) and EGFR T790M has a namor-level inhibition effect, intended to be used to treat EGFR T790M drug-resistant mutation non-small cell lung cancer patients.
The State Council's major documents may affect all pharmaceutical companies
Time of Update: 2021-02-11
from the above points of view, including strengthening the protection of drug patents, strengthening anti-monopoly of raw materials, the implementation of credit supervision of pharmaceutical recruitment, and promoting the development of Internet medical care are all very important measures to promote the development of the pharmaceutical industry.
A batch of drugs stopped supplying in Guizhou involving Wyeth Pharmaceuticals, Southwest Pharmaceuticals, Suzhou Second Leaf and so
Time of Update: 2020-10-07
announcement, from September 14, 2020, the drug in the x image below will be disqualified from winning the bid (hanging net).
at the same time, Guizhou Province requires medical institutions to cancel the winning bid (hanging net) qualified drugs, according to clinical needs to choose similar products procurement and use.
The transformation road of R & D first brother Hengrui
Time of Update: 2019-07-12
In 1970, Lianyungang Pharmaceutical Co., Ltd., a corner of Yanbian, Jiangsu Province, appeared anonymous in the huge Chinese pharmaceutical territory Twenty years later, sun piaoyang, the helmsman of